After a 48% One-Year Run, Investors Turn to Eli Lilly’s Next Set of Milestones

A Yahoo Finance column published June 6 framed a familiar question for Eli Lilly shareholders: after roughly a 48% gain over the past year, is the stock’s momentum becoming “too late” to trust, or has the market simply caught up to Lilly’s fundamental growth path? The commentary centers on whether expectations have moved ahead of results, even as Lilly’s latest updates show the company pressing forward on approvals, product availability, and guidance.

In its April 30 earnings release, Lilly reported that worldwide revenue rose 56% in the first quarter of 2026 to $19.8 billion, driven primarily by volume growth, with realized prices partially offset by Mounjaro and Zepbound pricing dynamics. Lilly also said first-quarter reported earnings per share rose 170% to $8.26, and non-GAAP EPS rose 156% to $8.55. The company paired that performance with an increase to its 2026 full-year outlook, raising revenue guidance to a range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to $35.50 to $37.00.

Lilly’s growth narrative has been tightly linked to its incretin portfolio, especially its weight-management and diabetes medicines. In the same report, the company highlighted regulatory progress, including U.S. FDA approval of Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems. Lilly positioned Foundayo as a GLP-1 pill designed to be taken any time of day without food or water restrictions, framing it as an effort to broaden the population that can benefit from GLP-1 therapies.

Beyond Foundayo, Lilly also pointed to incremental product and commercialization steps that could influence near-term demand. It said Zepbound (tirzepatide) is now available in multi-dose KwikPen, and it reported that in the U.S. Zepbound revenue increased 79% in the first quarter of 2026 to $4.1 billion, with strong demand cited as a driver and lower realized prices partially offset by adjustments to rebates and discounts.

Regulatory and policy access programs are now central to how quickly demand can scale and how prices can evolve. In Lilly’s Form 10-Q for the quarter ended March 31, the company described the Medicare GLP-1 Bridge program, under which Medicare beneficiaries will have access to discounted Lilly obesity medicines starting by July 1, 2026 through December 31, 2027, with states having an option to expand Medicaid access. Lilly said uptake from expanded access is unknown, and it warned that broader U.S. policy efforts to align domestic pricing with international benchmarks could affect pricing strategies, product demand, and revenue in certain markets.

The company’s filing also underscored concentration risk tied to its leading medicines. Lilly said Mounjaro and Zepbound accounted for 65% of its total revenue for the three months ended March 31, 2026, and it expects its cardiometabolic health products to remain a significant and growing portion of its business. That concentration means results can swing quickly if uptake in new “incretin channels and markets,” including U.S. Medicare access for Zepbound and Foundayo, develops slower or faster than expected.

What Lilly did not do in its published updates is directly answer the market-structure question posed by the Yahoo column, namely whether today’s share price already prices in a long run of growth or what specific valuation multiple the stock should deserve. Instead, Lilly’s disclosures emphasize guidance, regulatory approvals, and product access milestones, while its SEC filing leaves key areas open, including the unknown uptake of Medicare and Medicaid expansion.